Description: Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Home Page: www.sppirx.com
SPPI Technical Analysis
Pilot House – Lewis Wharf
Boston,
MA
02110
United States
Phone:
617 586 3900
Officers
Name | Title |
---|---|
Mr. Thomas J. Riga | Pres, CEO & Director |
Ms. Nora E. Brennan | Exec. VP & Chief Financial Officer |
Mr. Keith M. McGahan J.D., L.L.M. | Exec. VP, Chief Legal Officer & Corp. Sec. |
Dr. Francois J. Lebel FRCPC, M.D. | Exec. VP & Chief Medical Officer |
Mr. Bimal R. Shah | VP of Corp. & Bus. Devel. |
Mr. Michael A. Grabow | Exec. VP & Chief Bus. Officer |
Dr. Lyndah K. Dreiling M.B.A., M.D. | Sr. VP of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 4.7483 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 2.3953 |
Price-to-Sales TTM: | 0 |
IPO Date: | 1996-09-26 |
Fiscal Year End: | December |
Full Time Employees: | 163 |